Kazia Therapeutics (KZIA) Equity Average (2018 - 2025)
Kazia Therapeutics' Equity Average history spans 5 years, with the latest figure at -$6.0 million for Q2 2025.
- For Q2 2025, Equity Average fell 920.61% year-over-year to -$6.0 million; the TTM value through Jun 2025 reached -$6.0 million, down 920.61%, while the annual FY2025 figure was -$6.0 million, 920.61% down from the prior year.
- Equity Average reached -$6.0 million in Q2 2025 per KZIA's latest filing, down from $726147.7 in the prior quarter.
- In the past five years, Equity Average ranged from a high of $13.8 million in Q2 2022 to a low of -$6.0 million in Q2 2025.
- Average Equity Average over 4 years is $4.8 million, with a median of $5.6 million recorded in 2023.
- Peak YoY movement for Equity Average: fell 23.55% in 2023, then plummeted 920.61% in 2025.
- A 4-year view of Equity Average shows it stood at $13.8 million in 2022, then dropped by 23.55% to $10.6 million in 2023, then crashed by 93.13% to $726147.7 in 2024, then crashed by 920.61% to -$6.0 million in 2025.
- Per Business Quant, the three most recent readings for KZIA's Equity Average are -$6.0 million (Q2 2025), $726147.7 (Q2 2024), and $10.6 million (Q2 2023).